Annual Operating Expenses
$316.54 M
+$95.97 M+43.51%
December 31, 2023
Summary
- As of February 12, 2025, AMLX annual total operating expenses is $316.54 million, with the most recent change of +$95.97 million (+43.51%) on December 31, 2023.
- During the last 3 years, AMLX annual operating expenses has risen by +$277.54 million (+711.54%).
- AMLX annual operating expenses is now at all-time high.
Performance
AMLX Operating Expenses Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly Operating Expenses
$39.06 M
-$5.93 M-13.18%
September 30, 2024
Summary
- As of February 12, 2025, AMLX quarterly total operating expenses is $39.06 million, with the most recent change of -$5.93 million (-13.18%) on September 30, 2024.
- Over the past year, AMLX quarterly operating expenses has dropped by -$39.69 million (-50.40%).
- AMLX quarterly operating expenses is now -59.79% below its all-time high of $97.16 million, reached on December 31, 2023.
Performance
AMLX Quarterly Operating Expenses Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Operating Expenses Formula
Operating Expenses = Selling, General & Administrative (SG&A) Expenses + Research & Development (R&D) Expenses + Depreciation & Amortization + Other Operating Expenses
AMLX Operating Expenses Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | +43.5% | -50.4% |
| 3 y3 years | +711.5% | -50.4% |
| 5 y5 years | +2235.4% | -50.4% |
AMLX Operating Expenses Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3-year | at high | +282.8% | -59.8% | +38.0% |
| 5 y | 5-year | at high | +2235.4% | -59.8% | +354.7% |
| alltime | all time | at high | +2235.4% | -59.8% | +354.7% |
Amylyx Pharmaceuticals Operating Expenses History
| Date | Annual | Quarterly |
|---|---|---|
| Sep 2024 | - | $39.06 M(-13.2%) |
| Jun 2024 | - | $44.99 M(-52.3%) |
| Mar 2024 | - | $94.37 M(-2.9%) |
| Dec 2023 | $316.54 M(+43.5%) | $97.16 M(+23.4%) |
| Sep 2023 | - | $78.75 M(+8.7%) |
| Jun 2023 | - | $72.44 M(+6.2%) |
| Mar 2023 | - | $68.20 M(+7.1%) |
| Dec 2022 | $220.58 M | $63.66 M(+16.0%) |
| Date | Annual | Quarterly |
|---|---|---|
| Sep 2022 | - | $54.85 M(+1.1%) |
| Jun 2022 | - | $54.25 M(+13.5%) |
| Mar 2022 | - | $47.81 M(+68.9%) |
| Dec 2021 | $82.69 M(+112.0%) | $28.32 M(+23.5%) |
| Sep 2021 | - | $22.92 M(+23.3%) |
| Jun 2021 | - | $18.59 M(+44.4%) |
| Mar 2021 | - | $12.87 M(+49.8%) |
| Dec 2020 | $39.01 M(+187.8%) | $8.59 M |
| Dec 2019 | $13.55 M | - |
FAQ
- What is Amylyx Pharmaceuticals annual total operating expenses?
- What is the all time high annual operating expenses for Amylyx Pharmaceuticals?
- What is Amylyx Pharmaceuticals annual operating expenses year-on-year change?
- What is Amylyx Pharmaceuticals quarterly total operating expenses?
- What is the all time high quarterly operating expenses for Amylyx Pharmaceuticals?
- What is Amylyx Pharmaceuticals quarterly operating expenses year-on-year change?
What is Amylyx Pharmaceuticals annual total operating expenses?
The current annual operating expenses of AMLX is $316.54 M
What is the all time high annual operating expenses for Amylyx Pharmaceuticals?
Amylyx Pharmaceuticals all-time high annual total operating expenses is $316.54 M
What is Amylyx Pharmaceuticals annual operating expenses year-on-year change?
Over the past year, AMLX annual total operating expenses has changed by +$95.97 M (+43.51%)
What is Amylyx Pharmaceuticals quarterly total operating expenses?
The current quarterly operating expenses of AMLX is $39.06 M
What is the all time high quarterly operating expenses for Amylyx Pharmaceuticals?
Amylyx Pharmaceuticals all-time high quarterly total operating expenses is $97.16 M
What is Amylyx Pharmaceuticals quarterly operating expenses year-on-year change?
Over the past year, AMLX quarterly total operating expenses has changed by -$39.69 M (-50.40%)